US1523091007 - ADR
CENTESSA PHARMACEUTICALS-ADR
NASDAQ:CNTA (5/10/2024, 7:00:01 PM)
8.97
-0.58 (-6.07%)
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. The company is headquartered in Altrincham, Cheshire and currently employs 75 full-time employees. The company went IPO on 2021-05-28. The firm's advanced product candidate, SerpinPC, is a subcutaneously administered inhibitor of activated protein C (APC) being developed as a potential treatment for hemophilia. Leveraging its LockBody technology, it is developing an approach to selectively drive potent effector function activity, such as CD47 or CD3, into the tumor microenvironment (TME) while avoiding systemic toxicity. Its first LockBody product candidate, LB101, is a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody used in solid tumors. Its other programs consist of earlier-stage preclinical assets, including ORX750, an orally administered, selective Orexin Receptor-2 (OX2R) agonist for the treatment of narcolepsy (NT1) with potential expansion into other sleep disorders, and MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH).
CENTESSA PHARMACEUTICALS-ADR
3rd Floor, 1 Ashley Road
Altrincham CHESHIRE
P: 447391789784
CEO: Saurabh Saha
Employees: 75
Website: https://www.centessa.com/
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that...
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that...
Here you can normally see the latest stock twits on CNTA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: